TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26942487

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (PA)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Puberty and race
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Interaction effect of race and puberty
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Pubertal influence on fitness
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Associations between fitness and race/puberty
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Target group for fitness interventions
Number of subjects: 1011
Study: 25630353

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Lamotrigine, Gabapentin, Oxcarbazepine, Topiramate, Valproate
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Continued seizures, adverse events, and failure of initial treatment
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: 12-month remission
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Treatment withdrawal
Number of subjects: 1575
Study: 24378686

Group type: EXPERIMENTAL
Intervention: Sexuality discussions during health maintenance visits
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Conversations with explicit confidentiality discussions
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: African American adolescents
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Longer overall visit duration
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Asian physicians
Number of subjects: 253
Study: 23520669

Group type: EXPERIMENTAL
Intervention: Chemoradiation plus topical application of honey
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chemoradiation
Number of subjects: 55
Study: 20175802

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No ARB (Control)
Number of subjects: 30
Study: 17589364

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonresurfaced patella
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 32
Study: 15374773

Group type: EXPERIMENTAL
Intervention: 80 mg/day of atorvastatin
Number of subjects: 8888

Group type: COMPARATOR
Intervention: 20 mg/day of simvastatin (increased to 40 mg/day at week 24 if cholesterol levels remained high)
Number of subjects: 8888
Study: 11195258

Group type: EXPERIMENTAL
Intervention: Selective reuptake inhibitors (SRIs) reinstated at the same daily dose as in the acute phase for 24 weeks
Number of subjects: 81
Study: 11229787

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specific drugs not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed study design features
Number of subjects: 0
Study: 9204594

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 28 days, amoxicillin 3 x 500 mg for 7 days, metronidazole 3 x 500 mg for 5 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 28 days, ACA (amoxicillin 500 mg plus clavulanic acid 125 mg) 3 x 625 mg for 7 days, metronidazole 3 x 500 mg for 5 days
Number of subjects: 60
Study: 8128836

Group type: EXPERIMENTAL
Intervention: Physostigmine (intravenous, 2 hours)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine (THA, mean dose 104 ± 20 mg/day, 6 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: THA + lecithin (6 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (6 weeks)
Number of subjects: 27
Study: 3602101

Group type: EXPERIMENTAL
Intervention: Wet Ice (WI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dry Ice (DI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cryogenic Packs (CGP)
Number of subjects: 10
Study: 2202548

Group type: EXPERIMENTAL
Intervention: Fenticonazole (600 mg vaginal ovule)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Clotrimazole (500 mg vaginal tablet)
Number of subjects: 153
Study: 1093551

Group type: EXPERIMENTAL
Intervention: Ibuprofen 2400 mg/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ibuprofen (both dosages)
Number of subjects: 41
Study: 30378456

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 27814307

Group type: EXPERIMENTAL
Intervention: Shock wave therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo shock wave therapy
Number of subjects: 40
Study: 24971676

Group type: EXPERIMENTAL
Intervention: High-intensity running training (TRA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 16
Study: 21928913

Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release (12.5 mg)
Number of subjects: 15
Study: 19574798

Group type: EXPERIMENTAL
Intervention: Actinomycin D (Act‐D) 10 microg/kg per day for 5 days every 2 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Methotrexate-folinic acid (MTX‐FA) 1 mg/kg per day on days 1, 3, 5, and 7 with folinic acid 0.1 mg/kg per day on days 2, 4, 6, and 8 every 2 weeks
Number of subjects: 49
Study: 17610766

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy using PSSCogReHab for 10 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Matched control group (no intervention)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy control participants (no intervention)
Number of subjects: 12
Study: 15117561

Group type: EXPERIMENTAL
Intervention: Natural honey (75 g in 250 mL of water)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dextrose solution (75 g in 250 mL of water)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Artificial honey (35 g dextrose and 40 g fructose in 250 mL of water)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Honey solution (administered for 15 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Honey (administered for 15 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Honey (70 g)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Honey (30 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sucrose (30 g)
Number of subjects: 40
Study: 11961050

Group type: EXPERIMENTAL
Intervention: Intravesical ALA (1.328 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous ALA (100 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral ALA (100 mg)
Number of subjects: 14
Study: 9792048

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy and surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 7891249

Group type: EXPERIMENTAL
Intervention: Subgingival chlorexidine gel
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Subgingival tetracycline paste
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 2105048

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 92
Study: 351906

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31140432

Group type: EXPERIMENTAL
Intervention: Web-based instruction (WI), virtual reality (VR), and simulation exercise (SE) in three different instructional sequences (WI-VR-SE, WI-SE-VR, SE-WI-VR)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: SE-WI-VR
Number of subjects: 198

Group type: COMPARATOR
Intervention: WI-VR-SE and WI-SE-VR
Number of subjects: 198
Study: 28027521

Group type: EXPERIMENTAL
Intervention: Severe infection during NACT (defined as febrile neutropenia or any other grade III-IV infective adverse event)
Number of subjects: 1856

Group type: EXPERIMENTAL
Intervention: High expression of the IRF7 gene signature (N=160)
Number of subjects: 1856

Group type: EXPERIMENTAL
Intervention: High expression of the IRF7 gene signature
Number of subjects: 1856
Study: 25880388

Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Fields (PEMF)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard health care (placebo)
Number of subjects: 102
Study: 24696570

Group type: EXPERIMENTAL
Intervention: Sameera Pannaga Rasa at a dose of 30 mg twice a day for 4 weeks along with Nagavallidala (leaf of Piper betel Linn.)
Number of subjects: 52
Study: 21358290

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ketorolac 0 mg
Number of subjects: 12
Study: 19073361

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Family physician usual care (control)
Number of subjects: 40
Study: 17604744

Group type: EXPERIMENTAL
Intervention: Low-fat eating pattern (<20% energy from fat, > or = 5 servings fruits/vegetables daily, and > or = 6 servings grains daily)
Number of subjects: 19541

Group type: EXPERIMENTAL
Intervention: Low-fat eating pattern maintenance
Number of subjects: 19541
Study: 15078732

Group type: EXPERIMENTAL
Intervention: Firefighters who arrived before/during the WTC collapse
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Firefighters who arrived 1 to 2 days after the collapse
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Firefighters who arrived 3 to 7 days after the collapse
Number of subjects: 362

Group type: COMPARATOR
Intervention: Unexposed firefighters
Number of subjects: 362
Study: 11978282

Group type: EXPERIMENTAL
Intervention: Pfannenstiel incision
Number of subjects: 97

Group type: COMPARATOR
Intervention: Maylard incision
Number of subjects: 97
Study: 9786094

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 8600742

Group type: EXPERIMENTAL
Intervention: Nonaugmented repair using the Palmer technique
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Repair with synthetic augmentation
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Repair with biologic augmentation (patellar tendon)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: New and complete ruptures of one of the menisci
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Subcortical bone changes in the femoral condyles
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging signals in the repaired ligament augmented with the patellar tendon
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nonaugmented and ligament augmentation device‐augmented repairs
Number of subjects: 52
Study: 2806701

Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General practitioners' agreement to participate in a subsequent study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General practitioners' agreement for patient participation
Number of subjects: 0
Study: 1234497

Group type: EXPERIMENTAL
Intervention: ICI 66,082 (200 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water (control treatment)
Number of subjects: 6
Study: 31518599

Group type: EXPERIMENTAL
Intervention: Hard-clip finger pulse oximeter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrocardiogram (ECG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smartphone application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soft-clip oximeter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hard-clip oximeter
Number of subjects: 0
Study: 29793516

Group type: EXPERIMENTAL
Intervention: Short Rest (SR) of 1 min between exercise sets (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Full Rest (FR) of 4 min between exercise sets (n=10)
Number of subjects: 20
Study: 27621608

Group type: EXPERIMENTAL
Intervention: T+O 5/5 μg
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: T+O 2.5/5 μg
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: T+O 5/5 μg and T+O 2.5/5 μg
Number of subjects: 413
Study: 24559009

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with physical exercise (MEDE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low fat and rich in complex carbohydrates diet with physical exercise (CHOE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mediterranean diet (MED)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low fat and rich in complex carbohydrates diet (CHO)
Number of subjects: 36
Study: 22708881

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waiting list condition (start cognitive behaviour therapy after 6 months)
Number of subjects: 57
Study: 21163776

Group type: EXPERIMENTAL
Intervention: e-therapy program (n = 78)
Number of subjects: 156

Group type: COMPARATOR
Intervention: waiting list control group (n = 78)
Number of subjects: 156
Study: 18372693

Group type: EXPERIMENTAL
Intervention: Exercise (treadmill under LBNP and flywheel)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nutrition (daily protein supplement)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study: 16425428

Group type: EXPERIMENTAL
Intervention: Lamivudine (LAM) treatment
Number of subjects: 156

Group type: COMPARATOR
Intervention: Genotype D, CD, and non-classified type
Number of subjects: 156

Group type: COMPARATOR
Intervention: Non-classified types
Number of subjects: 156
Study: 11756059

Group type: EXPERIMENTAL
Intervention: Modified fats (lipase-structured fat, chemically structured fat, physically mixed fat)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional fat (rapeseed oil)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All 4 test fats
Number of subjects: 11
Study: 9526817

Group type: EXPERIMENTAL
Intervention: Atorvastatin 5, 20, and 80 mg/day
Number of subjects: 2689

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 2689

Group type: EXPERIMENTAL
Intervention: All statins
Number of subjects: 2689

Group type: EXPERIMENTAL
Intervention: Baseline triglyceride levels
Number of subjects: 2689

Group type: EXPERIMENTAL
Intervention: Triglyceride/LDL cholesterol ratio
Number of subjects: 2689
Study: 7857347

Group type: EXPERIMENTAL
Intervention: pidotimod
Number of subjects: 120
Study: 2777499

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (dl-alpha-tocopherol IM, 175 mg/kg over four weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (non-supplemented infants)
Number of subjects: 29
Study: 1090103

Group type: EXPERIMENTAL
Intervention: Baclofen (Lioresal)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 17
Study: 31943301

Group type: EXPERIMENTAL
Intervention: New complete dentures (CDs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Old and unsatisfactory complete dentures (CDs)
Number of subjects: 20
Study: 30657230

Group type: EXPERIMENTAL
Intervention: I Can Cope (ICC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Open Airways for Schools (OAS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 104
Study: 29417786

Group type: EXPERIMENTAL
Intervention: Knowledge assessment regarding vaccine preventable diseases
Number of subjects: 177
Study: 26238111

Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment (manual acupuncture plus electroacupuncture)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture control (sham acupuncture plus placebo acupuncture without electrical stimulation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture control
Number of subjects: 120
Study: 24145706

Group type: EXPERIMENTAL
Intervention: Sevoflurane and nitrous oxide
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sevoflurane and air
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Propofol and nitrous oxide
Number of subjects: 52

Group type: COMPARATOR
Intervention: Propofol and air
Number of subjects: 52
Study: 21038106

Group type: EXPERIMENTAL
Intervention: Target biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Step biopsy
Number of subjects: 0
Study: 18703549

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Addition of dorzolamide/timolol fixed combination (DTFC) to latanoprost monotherapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Latanoprost monotherapy
Number of subjects: 31
Study: 16939542

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20-80 mg/day
Number of subjects: 6801

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6801

Group type: COMPARATOR
Intervention: Fluvastatin vs Placebo
Number of subjects: 6801
Study: 14648726

Group type: EXPERIMENTAL
Intervention: Ligasure Vessel Sealing System
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional haemostatic methods
Number of subjects: 80
Study: 11095257

Group type: EXPERIMENTAL
Intervention: PTMR with a holmium:YAG laser plus continued medical treatment
Number of subjects: 221

Group type: COMPARATOR
Intervention: Continued medical treatment only
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: PTMR
Number of subjects: 221

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 221
Study: 8628460

Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg rHCNTF
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: 15 micrograms/kg rHCNTF
Number of subjects: 730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study: 8233620

Group type: EXPERIMENTAL
Intervention: Lambda-cyhalothrin impregnated bed nets
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Maloprim
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 2440626

Group type: EXPERIMENTAL
Intervention: Cisplatinum alone or in combination with bleomycin, methotrexate or 5-fluorouracil
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cisplatinum treatment
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cisplatinum treatment in advanced previously untreated disease
Number of subjects: 129
Study: 29908670

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg
Number of subjects: 499

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 499
Study: 25495390

Group type: EXPERIMENTAL
Intervention: Treated low thyroid hormone group
Number of subjects: 480

Group type: COMPARATOR
Intervention: Untreated low thyroid hormone group
Number of subjects: 480

Group type: COMPARATOR
Intervention: Normal thyroid functioning group
Number of subjects: 480
Study: 22272730

Group type: EXPERIMENTAL
Intervention: mild procedure
Number of subjects: 38

Group type: COMPARATOR
Intervention: Epidural steroid injection (ESI)
Number of subjects: 38
Study: 20194711

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Amylin infusion
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GLP-1 and amylin infusions
Number of subjects: 23
Study: 19148430

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15839293

Group type: EXPERIMENTAL
Intervention: Multidisciplinary case management model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient education materials and modified clinical policy
Number of subjects: 0
Study: 12220763

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 211

Group type: COMPARATOR
Intervention: External pneumatic compression
Number of subjects: 211
Study: 10486678

Group type: EXPERIMENTAL
Intervention: 110 dB noise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 95 dB noise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 120 dB noise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation (0 dB)
Number of subjects: 12
Study: 7762497

Group type: EXPERIMENTAL
Intervention: Long-acting diltiazem 300 mg/day and aspirin 160 mg/day
Number of subjects: 920

Group type: COMPARATOR
Intervention: Aspirin 160 mg/day alone
Number of subjects: 920
Study: 2086672

Group type: EXPERIMENTAL
Intervention: Interferon-beta ser (IFN-beta ser) 4.5 x 10(6) units
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Interferon-beta ser (IFN-beta ser) 90 x 10(6) units
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Interferon-beta ser (IFN-beta ser)
Number of subjects: 64
Study: 492836

Group type: EXPERIMENTAL
Intervention: Amoxicillin (15 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Amoxicillin (25 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 24
Study: 30982177

Group type: EXPERIMENTAL
Intervention: Fractional 1550-nm erbium-glass laser combined with 5% minoxidil
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5% minoxidil alone
Number of subjects: 30
Study: 27774838

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 4631

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4631
Study: 25398434

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 70
Study: 23844756

Group type: EXPERIMENTAL
Intervention: Oral combination of diosmin (300 mg/day), C. asiatica (15 mg/day) and Melilotus (160 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 70
Study: 22013932

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Nadroparin (excessive dosage)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Nadroparin (reduced dosage)
Number of subjects: 76
Study: 19211706

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 160 mg/day
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 80 mg/day
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 240 mg/day
Number of subjects: 322
Study: 16430930

Group type: EXPERIMENTAL
Intervention: Human contact session (45 min of interaction including playing, grooming, petting, and reviewing basic obedience commands)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No human contact session
Number of subjects: 0